XORTX Reminds Shareholders to Vote forward of the Proxy Voting Deadline for the Firm’s Upcoming Annual and Particular Assembly of Shareholders

Article content material

The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26, 2023.

Article content material

Article content material

CALGARY, Alberta, June 23, 2023 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Firm”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage medical pharmaceutical firm centered on growing modern therapies to deal with progressive kidney illness, want to remind shareholders that they’ve till 10:00 a.m. (Calgary time) on Monday, June 26, 2023 to vote their shares for the Firm’s upcoming annual and particular assembly of shareholders to be held on Wednesday, June 28, 2023 at 10:00 a.m. (Calgary time) (the “Assembly”).

Dr. Allen Davidoff, CEO of XORTX acknowledged, “XORTX has made substantial advances in the course of the previous 12 months guided by our skilled and expert R&D workforce and our broadly skilled board of administrators.  Because the Firm advances our late stage program in ADPKD towards the beginning of registration medical trial initiation, the Firm’s reliance upon our board of administrators particular person licensing, partnering and commercialization abilities will improve considerably.  Shareholders are inspired to vote and help the resolutions being voted at this 12 months’s Assembly to help a secure course of towards licensing deal and the purpose of constructing a excessive worth firm.”

Article content material

Article content material

Shareholders are urged to fastidiously learn the data round in reference to the Assembly. A duplicate of the data round and all different assembly supplies is obtainable on SEDAR at www.sedar.com and on XORTX’s web site at www.xortx.com. XORTX’s board of administrators recommends shareholders vote FOR all the proposed resolutions.

YOUR VOTE IS IMPORTANT REGARDLESS OF THE NUMBER OF SHARES YOU OWN.
PLEASE VOTE TODAY. THE PROXY CUT-OFF IS MONDAY, JUNE 26, 2023
AT 10 A.M. MOUNTAIN TIME.

Shareholder Help

Shareholders who’ve questions, or want help with voting their shares, ought to contact Laurel Hill Advisory Group, the proxy solicitation agent, by phone at +1 877-452-7184 (North America toll free) or + 1 416-304-0211 (exterior North America), or by e-mail at help@laurelhill.com.

Article content material

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical firm with two clinically superior merchandise in improvement: 1) our lead, XRx-008 program for ADPKD; and a couple of) our secondary program in XRx-101 for acute kidney and different acute organ harm related to Coronavirus / COVID-19 an infection. As well as, XRx-225 is a pre-clinical stage program for Sort 2 Diabetic Nephropathy. XORTX is working to advance its medical improvement stage merchandise that concentrate on aberrant purine metabolism and xanthine oxidase to lower or inhibit manufacturing of uric acid. At XORTX, we’re devoted to growing drugs to enhance the standard of life and future well being of sufferers. Further data on XORTX is obtainable at www.xortx.com.

Article content material

For extra data, please contact:

Neither the TSX Enterprise Alternate nor Nasdaq has authorized or disapproved the contents of this information launch. No inventory alternate, securities fee or different regulatory authority has authorized or disapproved the data contained herein.

Ahead Trying Statements

This press launch comprises categorical or implied forward-looking statements pursuant to U.S. Federal securities legal guidelines. These forward-looking statements and their implications are based mostly on the present expectations of the administration of XORTX solely, and are topic to various elements and uncertainties that would trigger precise outcomes to vary materially from these described within the forward-looking statements. Besides as in any other case required by legislation, XORTX undertakes no obligation to publicly launch any revisions to those forward-looking statements to mirror occasions or circumstances after the date hereof or to mirror the incidence of unanticipated occasions. Extra detailed details about the dangers and uncertainties affecting XORTX is contained beneath the heading “Threat Elements” in XORTX’s Registration Assertion on Type F-1 filed with the SEC, which is obtainable on the SEC’s web site, www.sec.gov (together with any paperwork forming a component thereof or integrated by reference therein), in addition to in our stories, public disclosure paperwork and different filings with the securities commissions and different regulatory our bodies in Canada, which can be found on www.sedar.com.

Article content material